Reimbursement

For your convenience, below are the NDC, HCPCS, CPT, and ICD-9-CM reimbursement codes for Humate-P^®. (Note: All codes should be verified between the provider and the payer.)

Our Reimbursement Resource Center provides additional information on insurance matters, coverage trends, patient assistance, and more.

Or, call CSL Behring's Reimbursement Answerline (1-800-676-4266) for assistance with individual case inquiries on a variety of reimbursement services, including:

• claim processing reviews
• appeals
• insurance investigations into product coverage
• prior approvals for therapies authorization

You can also write to:
CSL Behring
1020 First Avenue
P.O. Box 61501
King of Prussia, PA 19406-0901
Patient Assistance Program

Important Safety Information

Antihemophilic Factor/von Willebrand Factor Complex (Human), Dried, Pasteurized, Humate-P^® is indicated in adult patients for treatment and prevention of bleeding in hemophilia A (classical hemophilia). Humate-P^® is also indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate.

Humate-P^® is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations or to any of its components.

Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement, especially in the setting of known risk factors for thrombosis. Caution should be exercised and antithrombotic measures considered.

Humate-P^® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Although few adverse reactions have been reported the most common are allergic-anaphylactic reactions, including urticaria, chest tightness, rash, pruritus, edema, shock, chills and fever, and hypervolemia. For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding.

Please see accompanying full prescribing information for Humate-P^®.

The information provided herein is solely for use by physicians and healthcare professionals in the United States. The CSL Behring product listed may not have been approved in other countries and may not be available everywhere.